BioCryst Pharmaceuticals (BCRX) Earnings Date, Estimates & Call Transcripts $8.20 -0.10 (-1.20%) Closing price 04:00 PM EasternExtended Trading$8.12 -0.08 (-0.98%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BioCryst Pharmaceuticals Earnings Summary BioCryst Pharmaceuticals announced Q2 2025 earnings on August 4, 2025, reporting an EPS of $0.15, which beat analysts' consensus estimates of $0.03 by $0.12. Quarterly revenue rose 49.5% year-over-year to $163.35 million, above analyst estimates of $149.59 million. With a trailing EPS of -$0.18, BioCryst Pharmaceuticals' earnings are expected to grow next year, from ($0.36) to ($0.07) per share. Latest Q2 Earnings DateAug. 4EstimatedConsensus EPS (Aug. 4) $0.03 Actual EPS (Aug. 4) $0.15 Beat By $0.12 Actual Revenue (Aug. 4) $163.35MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Slide Deck Quarterly Report (10-Q)Slide DeckFull Screen Slide DeckPowered by Get BioCryst Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCryst Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataBCRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BCRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. BioCryst Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20251-$0.06-$0.06-$0.06Q2 20252$0.02$0.10$0.06Q3 20252$0.02$0.07$0.05Q4 20252$0.03$0.04$0.04 FY 2025 7 $0.01 $0.15 $0.08 Q1 20261$0.17$0.17$0.17Q2 20261$0.22$0.22$0.22Q3 20261$0.18$0.18$0.18Q4 20261$0.24$0.24$0.24 BioCryst Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025$0.03$0.15+$0.12$0.02$149.59M$163.35M2/24/2025Q4 2024-$0.07-$0.13 -$0.06-$0.13$126.64M$131.50M11/4/2024Q3 2024-$0.07-$0.07--$0.07$113.99M$117.10M8/5/2024Q2 2024-$0.17-$0.06+$0.11-$0.06$98.30M$109.30M5/6/2024Q1 2024-$0.23-$0.17+$0.06-$0.17$85.62M$92.80M2/26/2024Q4 2023-$0.24-$0.28 -$0.04-$0.25$89.19M$93.40M11/2/2023Q3 2023-$0.25-$0.19+$0.06-$0.19$86.54M$86.74M BioCryst Pharmaceuticals Earnings - Frequently Asked Questions When did BioCryst Pharmaceuticals announce their last quarterly earnings? BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earning data on Monday, August 4, 2025. Learn more on BCRX's earnings history. What guidance has BioCryst Pharmaceuticals issued on next quarter's earnings? BioCryst Pharmaceuticals issued an update on its FY 2025 earnings guidance on Friday, August, 8th. The company issued revenue guidance of $580.0 million-$600.0 million, compared to the consensus revenue estimate of $612.0 million. Did BioCryst Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) reported $0.15 earnings per share (EPS) to beat the analysts' consensus estimate of $0.03 by $0.12. Learn more on analysts' earnings estimate vs. BCRX's actual earnings. How can I listen to BioCryst Pharmaceuticals' earnings conference call? The conference call for BioCryst Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read BioCryst Pharmaceuticals' conference call transcript? The conference call transcript for BioCryst Pharmaceuticals' latest earnings report can be read online. Read Transcript How much revenue does BioCryst Pharmaceuticals generate each year? BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded annual revenue of $450.71 million. How much profit does BioCryst Pharmaceuticals generate each year? BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded net income of -$88.88 million. BCRX has generated -$0.18 earnings per share over the last four quarters. What is BioCryst Pharmaceuticals' price-to-earnings ratio? BioCryst Pharmaceuticals (NASDAQ:BCRX) has a . The price/earnings-to-growth ratio is 1.89. What is BioCryst Pharmaceuticals' EPS forecast for next year? BioCryst Pharmaceuticals' earnings are expected to grow from ($0.36) per share to ($0.07) per share in the next year. More Earnings Resources from MarketBeat Related Companies MDGL Earnings Date IONS Earnings Date RGEN Earnings Date ALKS Earnings Date LGND Earnings Date FOLD Earnings Date CLDX Earnings Date DVAX Earnings Date MNKD Earnings Date INVA Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Post-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove It This page (NASDAQ:BCRX) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access